Exhibit 99.1

Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results

—  Enrolling patients in three Phase 1 clinical trials for BLU-285 and BLU-554  —

—  Selected BLU-667 as a development candidate for its RET program  —

—  Ended year with $162.7 million in cash and cash equivalents  —

CAMBRIDGE, Mass., March 11,  2016 – Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2015.

“Our evolution into a multi-program clinical-stage company in 2015 has provided an important validation of our platform and generated multiple opportunities for corporate and clinical milestones for this year and beyond,” said Jeff Albers, Chief Executive Officer of Blueprint Medicines. “In addition to completing our initial public offering, we successfully began enrolling patients in two Phase 1 clinical trials and recently enrolled our first patient in our third Phase 1 clinical trial. We also entered into a strategic collaboration with Alexion to advance drug candidates for an undisclosed kinase target that is the driver of a rare genetic disease, and in December, we selected BLU-667 as a development candidate for our RET program. Looking forward, we anticipate several significant milestones this year. By the end of 2016, we expect preliminary data for each of our three Phase 1 clinical trials to be available, we plan to file an investigational new drug (IND) application for BLU-667 and we plan to nominate two more pre-clinical programs, including at least one program focused on kinases as therapeutic targets in cancer immunotherapy.”

Recent Business Highlights

Platform and Pipeline:

· Initiated third Phase 1 clinical trial:  InMarch 2016, Blueprint Medicines enrolled its first patient in its Phase 1 clinical trial of BLU-285 for the treatment of advanced systemic mastocytosis (SM).

· FDA grantedorphan drug designation for BLU-285 for gastrointestinal stromal tumors (GIST) and SM: In January 2016, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to BLU-285 for the treatment of GIST and SM. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.

· Presented preclinical data demonstrating anti-tumor activity of BLU-285 in models of acute myeloid leukemia (AML): In December 2015, at the 2015 American Society of Hematology (ASH) Annual Meeting,  Blueprint Medicines presented new preclinical data demonstrating the potential utility of BLU-285 in a subset of patients with AML containing a mutation in KIT Exon 17. BLU-285 administration in a systemic model of AML driven by a KIT Exon 17 mutation resulted in tumor regression and reduced disease burden compared to cytarabine-treated animals. In addition, several mice treated with BLU-285 had undetectable disease after 24 days.

· Selected BLU-667 as development candidate for RET program: In December 2015, Blueprint Medicines selected BLU-667 as adevelopment candidate for its RET program.  RET is a receptor tyrosine kinase that can become abnormally activated by mutations or fusions.  RET is a driver of

disease in non-small cell lung cancer and cancers of the thyroid, and Blueprint Medicines’ research suggests that RET may be a driver of disease in subsets of colon and breast cancer.BLU-667 is an orally available, potent and selective inhibitor of RET and RET resistance mutations that Blueprint Medicines predicts will be found in patients.  Blueprint Medicines plans to initiate 28-day Good Laboratory Practicetoxicology studies for BLU-667 in the first half of 2016 with the goal of identifying the dose limiting toxicity and anticipated first-in-human dose for BLU-667. Blueprint Medicines plans to file an IND for BLU-667 by the end of 2016.

Corporate:

· Strengthened executive leadership team and board of directors: In January 2016, Blueprint Medicines announced the appointment of Kathryn (Kate) Haviland as Chief Business Officer and the promotion of Anthony (Andy) Boral, M.D., Ph.D., to Chief Medical Officer.In February 2016, Blueprint Medicines appointed Lonnel Coats to its board of directors.

· Launched Mast Cell Connect with PatientCrossroads: In December 2015, Blueprint Medicines and PatientCrossroads launched Mast Cell Connect, a patient registry sponsored by Blueprint Medicines to advance the understanding of mastocytosis and help speed the development of new therapies. Mast Cell Connect, the first-ever open-model registry for patients with mastocytosis, is designed to bring the medical community greater insights about the needs of people living with the disease and to enable patients to sign up to receive notifications of clinical trials and other research studies. In addition, Blueprint Medicines launched a systemic mastocytosis awareness website, “Together with Systemic Mastocytosis” at www.systemicmastocytosis.com.

Fourth Quarter and Full Year 2015 Financial Results

· Cash Position:  As of December 31, 2015, cash and cash equivalents were $162.7 million, as compared to $47.2 million as of December 31, 2014. This increase was primarilydue to net proceeds of $154.8 million received upon the closing of Blueprint Medicines’ initial public offering in May 2015.  Blueprint Medicines expects that its existing cash and cash equivalents will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into at least the third quarter of 2017.

· Collaboration Revenue:  Collaboration revenues were $4.6million for the fourth quarter of 2015 and $11.4million for the year ended December 31, 2015. Blueprint Medicines did not record any collaboration revenue during the same periods for 2014.  The increase was due to Blueprint Medicines entering into a research, development and commercialization agreement with Alexion Pharma Holding (Alexion) in March 2015 to research, develop and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease.  Collaboration revenues for the fourth quarter of 2015 and the year ended December 31, 2015 reflected reimbursement from Alexion for work conducted by Blueprint Medicines under the parties’ collaboration, as well as a portion of the $15.0 million upfront payment and a  $1.8 million milestone payment, each of which will be amortized over the period of the research term, and a  $0.3 million milestone payment, which was recognized upon achievement in December 2015.

· R&D Expenses:  Research and development expenses were $16.4million for the fourth quarter of 2015, as compared to $11.3 million for the same period in 2014. This increase was primarily attributable to approximately $1.8 million associated with building Blueprint Medicines’ platform and advancing its discovery pipeline forward,  approximately $1.7 million in external clinical activities associated with advancing Blueprint Medicines’ two lead programs into clinical trials and approximately $1.5 million in increased personnel expense.  Research and development expenses

were $48.6million for the year ended December 31, 2015, as compared to $31.8 million for the year ended December 31, 2014. This increase was primarily attributable to approximately $6.0 million in increased personnel expense,approximately $6.0 million in external clinical activities associated with advancing Blueprint Medicines’ two lead programs into clinical trials, and approximately $5.4 million associated with building Blueprint Medicines’ platform and advancing its discovery pipeline forward. These increases were partially offset by $0.7 million of lower expenses associated with external IND-enabling pre-clinical and toxicology studies as well as manufacturing activities.

· G&A Expenses:  General and administrative expenses were $3.6million for the fourth quarter of 2015, as compared to $3.0 million for the same period in 2014. This increase was primarily attributable to approximately $0.2 million in increased personnel costs and stock-based compensation expense and approximately $0.2 million in increased professional fees. General and administrative expenses were $14.5million for the year ended December 31, 2015, as compared to $7.9 million for the year ended December 31, 2014. This increase was primarily attributable to approximately $3.5million in increased personnel costs and stock-based compensation expense and approximately $2.5million in increased professional fees and fees paid to members of Blueprint Medicines’ board of directors.

· Net Loss:  Net loss was $15.6million for the fourth quarter of 2015, or a basic and diluted net loss per share available to common stockholders of $0.58, as compared to a net loss of $14.5 million for the same period in 2014, or a basic and diluted net loss per share available to common stockholders of $10.44.Net loss was $52.8million for the year ended December 31, 2015, or a basic and diluted net loss per share available to common stockholders of $3.07, as compared to a net loss of $40.3 million for the year ended December 31, 2014, or a basic and diluted net loss per share available to common stockholders of $32.41.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding statements about plans and timelines for the clinical development of BLU-554 and BLU-285; the timing of clinical data or proof of concept for preclinical and clinical programs; the timing of regulatory submissions or filings, including, without limitation, an investigational new drug application for BLU-667;  potential benefits of orphan drug designation for BLU-285 for GIST and  SM, expectations regarding Blueprint Medicines’ existing cash and cash equivalents and Blueprint Medicines’ strategy, business plans and focus.The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.Any forward-looking statements in this press release are based on

management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines’ drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines’ drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission (SEC) on November 9, 2015, and other filings that Blueprint Medicines may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

	December 31,		December 31,
	2015		2014
Cash and cash equivalents	$	162,707	$	47,240
Unbilled accounts receivable		3,414		—
Working capital (1)		151,776		41,510
Total assets		178,898		49,925
Deferred revenue		13,640		—
Term loan payable		7,338		9,042
Lease incentive obligation		3,948		—
Warrant liability		—		365
Convertible preferred stock		—		114,811
Total stockholders’ equity (deficit)		143,979		(79,382)
(1)Blueprint Medicines defines working capital as current assets less current liabilities.

Blueprint Medicines Corporation

Condensed Statements of Operations Data

(in thousands, except per share data)

(unaudited)

	Three Months Ended				Years Ended
	December 31,				December 31,
	2015		2014		2015		2014
Collaboration revenue	$	4,635	$	—	$	11,400	$	—
Operating expenses:
Research and development		16,432		11,332		48,588		31,844
General and administrative		3,624		2,961		14,456		7,890
Total operating expenses		20,056		14,293		63,044		39,734
Other income (expense):
Other income (expense), net		6		(24)		(429)		(98)
Interest expense		(160)		(151)		(696)		(453)
Total other expense		(154)		(175)		(1,125)		(551)
Net loss	$	(15,575)	$	(14,468)	$	(52,769)	$	(40,285)
Convertible preferred stock dividends		—		(1,905)		(3,153)		(5,765)
Net loss applicable to common stockholders	$	(15,575)	$	(16,373)	$	(55,922)	$	(46,050)
Net loss per share applicable to common stockholders — basic and diluted	$	(0.58)	$	(10.44)	$	(3.07)	$	(32.41)
Weighted-average number of common shares used in net loss per share applicable to common stockholders — basic and diluted		26,962		1,568		18,236		1,421

Contact:

Investor Relations:

Kristin Williams

Blueprint Medicines Corporation

617-714-6674

KWilliams@blueprintmedicines.com

Media Relations:

Dan Quinn

Ten Bridge Communications, Inc.

781-475-7974

dan@tenbridgecommunications.com